Skip to content

AbbVie Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: October 30, 2026 results vs estimates

AbbVie Inc · E.ABBV.NYSE · United States
Use symbol E.ABBV.NYSE in our API & Excel add-in to retrieve this data ↓
290.79
(+0.02%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 20.91%

AbbVie Inc Forecast

AbbVie Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 20.9% a year, a typical one-standard-deviation range is 282.22–299.36 over a week, 273.23–308.35 over a month and 229.98–351.60 over a year. (Signals as of 1 Nov 2026.)

AbbVie Inc Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
AbbVie Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
AbbVie Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
AbbVie Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
AbbVie Inc
P/E
49.82x
Mid-range vs own history
QoQ −33.0%
YoY −71.6%
now 49.82449.04 low171.78 high
ⓘP/E As of 22 Nov 2026.See AbbVie Inc returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
AbbVie Inc
P/S
7.81x
Stretched vs own history
QoQ +7.1%
YoY +11.2%
now 7.80565.69 low8.11 high
ⓘP/S As of 22 Nov 2026.See AbbVie Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
AbbVie Inc
EV/EBITDA
23.27x
Mid-range vs own history
QoQ −7.6%
YoY −38.2%
now 23.268422.95 low36.99 high
ⓘEV/EBITDA As of 22 Nov 2026.See AbbVie Inc returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
AbbVie Inc
EV/Sales
8.87x
Stretched vs own history
QoQ +7.0%
YoY +9.8%
now 8.8686.7 low9.11 high
ⓘEV/Sales As of 22 Nov 2026.See AbbVie Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
AbbVie Inc
FCF Yield
3.7%
Weak vs own history
QoQ −5.6%
YoY −22.1%
now 3.66253.49 low5.59 high
ⓘFCF Yield As of 22 Nov 2026.See AbbVie Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
AbbVie Inc
Earnings Yield
2.0%
Mid-range vs own history
QoQ +49.3%
YoY +251.9%
now 2.00710.58 low2.04 high
ⓘEarnings Yield As of 22 Nov 2026.See AbbVie Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
AbbVie Inc
Dividend Yield
2.4%
Weak vs own history
QoQ −7.7%
YoY −14.2%
now 2.35562.29 low3.31 high
ⓘDividend Yield As of 22 Nov 2026.See AbbVie Inc returns when Dividend Yield looked like now →Opens Return analysis with the filter Dividend Yield within ±5% of today
AbbVie Inc
Market Cap
$515.3B
Highest in 5 years
QoQ +9.8%
YoY +23.1%
now 515279.88352,512 low522,793 high
ⓘMarket Cap As of 22 Nov 2026.See AbbVie Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
AbbVie Inc
Net Debt
$70.1B
High vs own history
QoQ +9.1%
YoY +11.2%
now 7012963,072 low70,129 high
ⓘNet Debt As of 22 Nov 2026.See AbbVie Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
AbbVie Inc
Net Debt / EBITDA
2.79x
Mid-range vs own history
QoQ −8.1%
YoY −43.5%
now 2.78742.79 low4.93 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See AbbVie Inc returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
AbbVie Inc
Current Ratio
0.87x
Mid-range vs own history
QoQ +7.6%
YoY +20.0%
now 0.86960.67 low0.87 high
ⓘCurrent Ratio As of 22 Nov 2026.See AbbVie Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
AbbVie Inc
Quick Ratio
0.75x
Mid-range vs own history
QoQ +8.9%
YoY +24.6%
now 0.74650.56 low0.75 high
ⓘQuick Ratio As of 22 Nov 2026.See AbbVie Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
AbbVie Inc
Interest Coverage
5.87x
Mid-range vs own history
QoQ +28.6%
YoY +272.5%
now 5.87181.58 low5.87 high
ⓘInterest Coverage As of 22 Nov 2026.See AbbVie Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
AbbVie Inc
Piotroski F-Score
8
Strong vs own history
QoQ 0.0%
YoY +14.3%
now 85 low8 high
ⓘPiotroski F-Score As of 22 Nov 2026.See AbbVie Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
AbbVie Inc
Altman Z-Score
2.67
Strong vs own history
QoQ +4.8%
YoY +24.1%
now 2.66981.92 low2.77 high
ⓘAltman Z-Score As of 22 Nov 2026.See AbbVie Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for AbbVie Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

AbbVie Inc fundamentals: income statement, balance sheet & cash flow

AbbVie Inc reported revenue of $61.16bn and net income of $4.23bn in FY2025, the year ended 31 December 2025 — revenue up 8.6% and net income down 1.2% on the prior year. Free cash flow was $17.82bn. These figures are as reported in the filings, not restated: 17 fiscal years and 64 quarters of history, back to December 2009. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$61.16bn
+8.6%
Net income
$4.23bn
-1.2%
Gross margin
70.24%
Free cash flow
$17.82bn
-0.1%
Net debt
$63.84bn
Shares short (30 Oct 2026)
15.81m
3.32 days to cover
AbbVie Inc income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue61.1656.3354.3258.0556.20
Cost of revenue18.2016.9020.4217.4117.45
Gross profit42.9639.4333.9040.6438.75
Research & development9.1012.797.686.518.05
Operating income15.089.1412.7618.1217.92
EBITDA17.6314.9117.1724.1723.93
Interest expense2.892.812.222.232.42
Pre-tax income6.603.726.2513.4812.99
Income tax2.36-0.571.381.631.44
Net income4.234.284.8611.8411.54

Download AbbVie Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ABBV.NYSE&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 17 fiscal years and 64 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on AbbVie Inc

Recent MacroFinance research reports referencing AbbVie Inc, newest first.

Browse all financial research →

AbbVie Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to AbbVie Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How AbbVie Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how AbbVie Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About AbbVie Inc (United States)

AbbVie Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on AbbVie Inc

Frequently asked questions

What is AbbVie Inc?
AbbVie Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest AbbVie Inc price?
The latest close is 290.79 (1 Nov 2026), +0.02% on the day. The price at the top of the page refreshes during the trading day.
Is AbbVie Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is AbbVie Inc?
20-day realised volatility is 20.9% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 6.0% over a month and 2.9% over a week.
What factors affect AbbVie Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to AbbVie Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade AbbVie Inc?
58 backtested tactical asset allocation strategies trade AbbVie Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are AbbVie Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of AbbVie Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free AbbVie Inc historical data?
In the Free historical data section of this page: the last 10 years of AbbVie Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free AbbVie Inc historical data (last 10 years)

Browse or instantly download the last 10 years of AbbVie Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ABBV.NYSE&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20286.2
2026-11-19283.54
2026-11-18286.01
2026-11-17292.82
2026-11-16294.55
2026-11-13295.03
2026-11-12294.45
2026-11-11294.98
2026-11-10293.89
2026-11-09293.3
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.